NECTIN4 and neoplasm: Studies on the biology and pathology of Nectins and Necls has led to important innovations and clinical applications, such as FDA-approved therapy for treating locally advanced or metastatic urothelial carcinoma antibody–drug conjugate: enfortumab vendotin uses Nectin-4 as a target molecule for entering tumor cells [54,55].